Global Vaccine Congress - Second Conference
Sunday December 7, 2008
Plenary session 1 - Setting the scene
Chair: Shan Lu
  Ray Spier Welcome
11.00 - 11.10 Adel Mahmoud
Princeton University, USA 		Future of Vaccine Discovery
11.45 - 12.10 Hiroshi Kiyono
University of Tokyo, Japan 		Development of Self-Administrative Vaccine by MucoRiceTM System
12.10 - 12.35 Raymond Welsh
University of Massachusetts Medical School, USA 		Pathogenic epitopes, heterologous immunity, and vaccine design
12.35 - 1.00 Mark K. Slifka
Oregon Health & Science University, USA 		Duration of Immunity Following Vaccination:  How Long it Can Last and How We Can Make it Better
1.00 - 2.00 Lunch  
Plenary session 2 - Major Infectious Disease Targets
Chair: Shan Lu
2.00 - 2.10 Elizabeth Adams
NIAID, USA 		Oral 1 - The Reiterative Discovery Process – HIV Vaccine Prevention Research Moving Forward Post The STEP Trial
2.10 - 2.35 Shan Lu
University of Massachusetts Medical School, USA 		Developing HIV Vaccines With Protective Antibody Responses
2.35 - 3.00 Adrian Hill
The Jenner Institute, UK 		New Vectored Vaccines for Malaria
3.00 - 3.25 Michael J. Brennan
Aeras Global TB Vaccine Foundation, USA 		TB Vaccine Development
3.25 - 4.00 Exhibit hall and Coffee  
3.30 - 4.00 Poster Session Human Vaccines Infectious Disease
Human Vaccines Non Infectious Disease
Plenary session 3 - Non-traditional vaccines
Chair: Rino Rappouli
4.00 - 4.25 Annie de Groot
EpiVax Inc., USA 		Computer-driven Vaccine Design: From Concept to Reality
4.25 – 4.50 Polly Gregor
Memorial Sloan-Kettering Cancer Center, USA 		Of Mice and Men (and Dogs): Clinical Development of Xenogeneic DNA Vaccines for Cancer.
4.50 - 5.00 Eric Huang
University of California USA 		Oral 2 - Acne Vaccines Targeting P. acnes Virulent Factors
5.00 - 5.10 Marcus Hoerer
MediGene AG, Germany 		Oral 3 - Development of AAV as Potent B-cell Vaccine Directed Against Human IgE for the Treatment of Severe Allergic Asthma
5.10 - 5.20 William Decker
University of Texas MD Anderson Cancer Centre, USA 		Oral 4 - Th-1 Immunity is Regulated by Dendritic Cell Comparison of MHC Class I and Class II Antigens: Implications for Successful Immunotherapy of Neoplasia
5.20 - 5.30 Philippe Leff
National Institute of Psychiatry, Mexico 		Oral 5 - Preclinical Studies On The Generation of Conjugated Vaccines for Addictive Drugs
5.30 - 7.30 Opening reception - Poster & Exhibit hall
Monday December 8, 2008
Plenary sessions 4 – Adjuvants
Chair: Hiroshi Kiyono
8.30 - 8.55 Kate A. Fitzgerald
University of Massachusetts Medical School, USA 		Pattern Recognition Receptors and the Adjuvant Response
8.55 - 9.20 Dennis Klinman
NCI-Frederick, USA 		Use of CpG Oligonucleotides as a Vaccine Adjuvant
9.20 - 9.30 Angelika Banzhoff
Novartis, Germany 		Oral 6 - An MF-59 Adjuvanted H5N1 Clade 1 Pre-pandemic Vaccine Confers Cross-reactive Antibodies to a Clade 2 H5N1 Virus Strain
9.30 - 9.40 Stephane Heijmans
ResearchLink, Belgium 		Oral 7 - AS03-Adjuvanted Prepandemic Influenza Vaccine: High Immunogenicity In The Elderly
9.40 - 9.50 Stephanie Eisenbarth
Yale School of Medicine, USA 		Oral 8 - Aluminum Hydroxide Adjuvants Activate the Immune System Through the Nalp3 Inflammasome
9.50 - 10.00 Eric Tartour
Hopital Européen Georges Pompidou, France 		Oral 9 - The Non Toxic B Subunit of Shiga Toxin Coupled to Various Antigens Elicits Mucosal Humoral and Cellular Immune Responses.
10.00 - 10.10 Marcin Kwissa
Emory Vaccine Center, USA 		Oral 10 - Adjuvanting a DNA Vaccine With a TLR9 Ligand Plus Flt3 Ligand Results in Enhanced Cellular Immunity Against the Simian Immunodeficiency Virus
10.10 - 10.20 Bin Wang
China Agricultural University, China 		Oral 11 - Activation of MyD88 Dependent TLR 7/8 Pathway Leads to Cell Mediated Responses by Levamisole As A Potent Adjuvant for Therapeutic Vaccination Against HBV Infection
10.20 - 10.30 Wei Li
University of Massachusetts Medical School, USA 		Oral 12 - DNA Vaccine Prime Improved the Antigen-specific B Cell Memory and Longevity of B Cell Responses Against V Antigen of Yersinia Pestis in Mice
10.30 - 11.00 Exhibit hall and Coffee  
10.30 - 11.00 Poster Session Adjuvants
Delivery Systems
Late Breaker
Production & Other
Plenary sessions 5 - Delivery systems
Chair: Peter Nara
11.00 - 11.25 Bruce G. Weniger
Centers for Disease Control and Prevention, USA 		Vaccination Into or Onto the Skin: Advantages, Accomplishments, Actualizations, and Adumbrations of the Cutaneous Route
11.25 - 11.50 Dan Barouch
Harvard Medical School, USA 		Novel Adenovirus Vector-Based Vaccines for HIV-1
11.50 - 12.00 Julia Hurwitz
St. Jude Children's Research Hospital USA 		Oral 13 - Development of Sendai Virus-based Vaccines to Prevent Pediatric Respiratory Virus Infections
12.00 - 12.10 Tina Villar
Intercell USA Inc 		Oral 14 - Field Efficacy Results From a Field Trial Show a Patch Containing Heat Labile Enterotoxin from Escherichia coli (LT) Protects Against Travelers’ Diarrhea
12.10 - 12.20 David Chang, University of Queensland, Australia Oral 15 - West Nile virus DNA Vaccine Producing Single Round Infectious Particles Protects Mice From Lethal Encephalitis and Induce Virus-neutralising Antibodies in Horses
12.20 - 12.30 Brian Livinston, Ichor Medical Systems,  USA Oral 16 - Electroporation Mediated DNA Immunization: Comparative Performance Versus Classical Vaccine Approaches and Transition to Human Clinical Testing
12.30 - 2.15 Lunch  
12.30 - 1.30 Poster Session Adjuvants
Delivery Systems
Late Breaker
Production
Other
1.30 - 2.00 ISV Business Meeting Harbor Ballroom
Plenary sessions 6 - ISV President presentation
Chair: Ray Spier
2.15 - 3.15 Gregory A. Poland
Mayo Vaccine Research Group, USA 		Influenza Immunization of Health Care Workers: A Patient Safety Imperative
ISV selected abstract presentation
3.15 - 3.25 Jan Pravsgaard Christensen
University of Copenhagen, Denmark 		Oral 17 - Improved immunogenicity of Adenoviral Vaccines: Impact of Tethering the Vaccine Antigen to MHC-class II Associated Invariant Chain
3.25 - 3.35 Indresh Srivastava
Novartis Vaccines,  USA 		Oral 18 - Toward the Development of a SARS Vaccine
3.35 - 3.45 Mart Ustav
FIT Biotech Oy Eesti AS, Estonia 		Oral 19 - Development of the DNA Plasmid Based Genetic Vaccine Vectors, Which Use Segregation/Partitioning Functions of the Episomally Replicating DNA Viruses.
3.45 - 3.55 Vidya Arankalle (absent)
National Institute for Virology, India 		Oral 20 - Development of recombinant G protein-based vaccine for Chandipura virus
3.55 - 4.30 Exhibit hall and Coffee  
4.00 - 4.30 Poster Session Adjuvants, Delivery Systems
Late Breaker
Production
Other
Breakout session 1 - Vaccine production and clinical use
Harbor Ballroom 2 & 3
Chair: Bruce Weniger
4.30 - 4.55 Rich Costantino
USA 		Stability of Vaccines
4.55 - 5.05 Stephan Zweig
Clinisense Corporation, USA 		Oral 21 - Vaccine Stability Monitoring Using the LifeTrack® Electronic Stability Monitor
5.05 - 5.15 Derek Gregg
Vandalia Research, USA 		Oral 22 - System and Process for Large-Scale DNA Vaccine Production by PCR
5.15 - 5.25 Denis Leclerc
Laval University, Canada 		Oral 23 - Development of an Universal Influenza A Vaccine Using an Innovative Plant Virus Based Platform
5.25 - 5.35 Hana El Sahly, Baylor College of Medicine, USA Oral 24 - Phase 1, Double-Blinded, Placebo-Controlled, Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
5.35 - 5.45 Derek Brown
RTI International Research, USA 		Oral 25 - Mother and Daughter Preferences and Willingness to Pay for HPV Vaccination
5.45 - 5.55 Mark Steinhoff
Cincinnati Childrens Hospital Medical Center, USA 		Oral 26 - Maternal Immunization: an Underutilized Strategy to Protect both Mothers and Infants
5.55 - 6.05 Cathy Panozzo
Center for Disease Control and Prevention, USA 		Oral 27 - Delayed Onset and Diminished Magnitude of Rotavirus Activity--United States, November 2007-May 2008
Breakout session 2 - Late Breakers Abstracts – 1
Harbor Ballroom 1
Chair: Bob Chen
4.30 - 4.40 Jan ter Meulen
Merck & Co, USA 		Oral 28 - Modeling of a Highly Conserved Influenza HA2 Epitope for Vaccination and Evaluation in the Mouse Challenge Model.
4.40 - 4.50 Myra Widjojoatmodjo
Netherlands Vaccine Institute, The Netherlands 		Oral 29 - A highly Attenuated Recombinant Human Respiratory Syncytial Virus Lacking the G Protein Confers Long Time Protection Against RSV Infection in Cotton Rats.
4.50 - 5.00 Maryann Giel-Moloney
Acambis, USA 		Oral 30 - RepliVax®: New Replication-Defective Flavivirus Vaccines and Vectors for Non-Flavivirus Immunogens
5.00 - 5.10 De-Chu Tang
Vaxin Inc, USA 		Oral 31 - Non-replicating Adenovirus-Vectored Avian Influenza Vaccine as a Rapid-Response Tool for Mitigating a Pandemic
5.10 - 5.20 Eryu Wang
University of Texas, USA 		Oral 32 - Chimeric Alphavirus Vaccines for Western Equine Encephalitis
5.20 - 5.30 Dorothee Herlyn
The Wistar Institute, USA 		Oral 33 - Antigens Recognized by Cytotoxic and Helper T Lymphocytes with Vaccine Potential for Cancer Patients
5.30 - 5.40 Peter Rottier
Utrecht University, The Netherlands 		Oral 34 - A Genetically Attenuated Feline Coronavirus Vaccine: Protection Against Feline Infectious Peritonitis (FIP) by Cellular Rather Than by Virus-Neutralizing Immunity
5.40 - 5.50 Aalzen De Haan
The Netherlands 		Oral 35 - Fusion Inactivation of H5N1 Whole Inactivated Virus (WIV) Vaccine Does Not Compromise its Superior Immunogenicity.
5.50 - 6.00 Cristina Nazarov
Uniformed Services University, USA 		Oral 36 - Down-Regulation of Influenza Viral Vaccination by CD4+25hi T-Regulatory Cells
Coaches depart from D St. entrance of the Westin Waterfront (concourse level) at 7.00pm
Tuesday December 9, 2008
Plenary session 7 - Novel Bacterial Vaccines
Chair: Jan ter Meulen
8.30 - 8.55 Rino Rappuoli
Novartis Vaccines and Diagnostics, Italy 		Vaccines: An Health Insurance of the 21st century
8.55 - 9.20 John W. Shiver
Merck and Co Inc., USA 		Development of a Novel Staphylococcus Aureus Vaccine Based on a Conserved Protein Antigen
9.20 - 9.45 Jennifer Schranz
Wyeth, USA 		Pneumococcal Conjugate Vaccines: What Do We Know and What Do We Need?
9.45 - 9.55 Carmen Giefing
Intercell AG, Austria 		Oral 37 - Development of a Full Coverage Pneumococcal Vaccine Comprising Highly Conserved Proteins With a Crucial Function in the Bacterial Life Cycle
9.55 - 10.05 Peter Dull
Novartis, USA 		Oral 38 - A Phase III Head-to-Head Comparison of a Novel Quadrivalent Meningococcal Conjugate Vaccine, MenACWY-CRM, With the Licensed Meningococcal ACWY Conjugate Vaccine, Menactra®, in Healthy Subjects 11-55 Years of Age
10.05 - 10.15 Yongqun He
University of Michigan, USA 		Oral 39 - Vaxign: a Web-based Vaccine Target Design Program for Reverse Vaccinology
10:15-10:25 Daniel Scott
Wyeth, USA 		Oral 40 - Safety & Immunologic Non-inferiority of 13-valent Pneumococcal Conjugate Vaccine Compared to 7-valent Pneumococcal Conjugate Vaccine Given with Routine Vaccines in Healthy Infants
10.25 - 11.00 Exhibit hall and Coffee  
10.30 - 11.00 Poster session Veterinary Vaccines
 Immunology/Animal Models
Plenary session 8 - Emerging Infectious Disease & Biodefense
Harbor Ballroom 2 & 3
Chair: John Oxford & Alan Barrett
11.00 - 11.25 Alan Barrett
University of Texas Medical Branch, USA 		Characterization of Type-specific and Dengue Complex Antigenic Sites on the Envelope Protein Domain III of Dengue Viruses
11.25 - 11.50 John S. Oxford
Retroscreen Virology Ltd, UK 		The Ferret and Human Models for Influenza Vaccine Evaluation
11.50 - 12.00 Trudy Morrison
University of Massachusetts Medical School, USA 		Oral 41 - The Immunogenicity and Efficacy of a Virus-like Particle Vaccine Candidate against Respiratory Syncytial Virus in Mice
12.00 - 12.10 Nicolas Sabarth, Baxter Innovations GmbH, Austria Oral 42 - Induction of Longitudinal Cross-Clade Anti-H5N1 Immunity and Protection by Homologous and Heterologous Prime-Boost Immunization Regimes with Whole Virus H5N1 Influenza Candidate vaccines
12.10 - 12.20 George Bettinger
University of Texas Medical Branch, USA 		Oral 43 - Genetic and Clinical Evaluation of MP-12: a live Attenuated Vaccine for Rift Valley Fever Virus (RVFV)
12.20 - 12.30 Igor Lukashevich
Institute of Human Virology, USA 		Oral 44 - A ML29 Reassortant Lassa Fever Vaccine is Safe and Induces Broad Cell-Mediated Protective Immune Responses in Experimental Animals
12.30 - 12.40 Hana El Sahly
Baylor College of Medicine, USA 		Oral 45 - Phase 1, Double-Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Reactogenicity of Francisella tularensis Live Vaccine Strain (LVS) Administered by the Scarification or Subcutaneous Route
Breakout session 3 - Late Breaker Abstracts – 2
Harbor Ballroom 1
Chair: John Shiver
11.00 - 11.10 Harry Hull
HF Hull & Associates, USA 		Oral 46 - Strategies for Achieving Efficient Implementation of an Expanded ACIP Recommendation for Influenza Vaccination of School-aged Children
11.10 - 11.20 Benoit Dervaux
CRESGE, France 		Oral 47 - The value of Information When Considering Introduction of a New Vaccine in the Immunisation Schedule: A Conjoint Analysis Conducted in Europe
11.20 - 11.30 David Klatzmann (absent)
UMR 7087 UPMC-CNRS, France 		Oral 48 - Rational Design and Standardized Evaluation of Novel Genetic Vaccines
11.30 - 11.40 Mauro Pistello
University of Pisa, Italy 		Oral 49 - Prime-Boost Vaccination with DNA-Transduced Autologous Lymphocytes Protects Against Fully Virulent Homologous Challenge in the Feline Immunodeficiency Virus AIDS Model
11.40 - 11.50 Tomonori Nochi
University of Tokyo, Japan 		Oral 50 - Exploit of Nanogel as a Novel Carrier of Mucosal Vaccine: Nanogel Mucosal Vaccine Effectively Induces Protective Immunity Against Botulinum Toxin
11.50 - 12.00 Wil Landman
Animal Health Service, The Netherlands 		Oral 51 - Vaccination of Broiler Chickens with Dry Powder Vaccines as an Alternative for Liquid Spray and Aerosol Vaccination
12.00 - 12.10 Dominique Schols
Rega Institute for Medical Research, Belgium 		Oral 52 - HIV-1 Resistance Towards CADA-induced CD4 Receptor-Targeted Inhibition is Associated with Increased Sensitivity to Neutralizing Antibodies.
12.10 - 12.20 Valentina Feodorova
Saratov State University, Russia 		Oral 53 - Yersinia pestis Live Vaccine with Improved Characteristics
12.20 - 12.30 Julie Milstien
University of Maryland School of Medicine, USA 		Oral 54 - Challenges and Potential Solutions to Innovative Vaccine Development in Developing Countries
12.30 - 2.00 Exhibit hall and Lunch  
12.45 - 1.15 Poster session Veterinary Vaccines
 Immunology/Animal Models
Plenary 9 - Vaccine Policy and public health issues
Chair: Ray Spier
2.00 -2.25 Dack Dalrymple
Dalrymple & Associates, LLC, USA 		Current & Future U.S. Government Funding for Vaccine R&D and Acquisition
2.25 - 2.50 Bob Chen
Centers for Disease Control and Prevention, USA 		Enhancing Vaccine Safety Assessment During Vaccine Development: Some Modest Proposals

2.50 - 3.15

Jon Andrus
Pan American Health Organization, USA

Implementing Vaccination Programs in Developing Countries
3.15 - 3.40 Peter Nara
Biological Mimetics Inc, USA 		Improving on Mother Nature's Immunogenicity
3.40 - 4.05 Ray Spier Dealing with Ethical Issues in the Area of Vaccines and Vaccination
Ray Spier and Shan Lu Closing Summary
   
Copyright© 2008. All Rights Reserved.